Global Integrin Beta 8 Market, By Disease (Arteriovenous malformation and Arrhythmogenic right ventricular cardiomyopathy), By Application (Flow cytometry, CyTOF and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

This gene encodes a single-pass type I membrane protein with a VWFA domain and four cysteine-rich repeats that belongs to the integrin beta chain family. Integrins are the main metazoan receptors for cell adhesion to extracellular matrix proteins, and they also play a role in certain cell-cell adhesions, transmembrane connections to the cytoskeleton, and activation of several intracellular signaling cascades in vertebrates. The Integrin beta-8 component is a glycosylated polypeptide of 95 kDa that is similar to other beta chain integrins. It forms a heterodimer with the Alpha-V chain, which is found in mature synapses in mouse and rat brains. The ITGB8 gene (Integrin Subunit Beta 8) codes for a protein. Arteriovenous Malformation and Arrhythmogenic Right Ventricular Cardiomyopathy are two diseases that have been linked to ITGB8. ITGB5 is a significant paralog of this gene.

Growth in business operations by emerging and small sized players

Integrin beta 8 is gaining traction as a potential of various disease and cancer therapeutic target. During the forecast period, the Integrin beta 8 market is anticipated to be propelled by ongoing clinical trials and studies on Integrin beta 8 as a new cancer therapeutic option. The increasing focus on new research by government bodies and key companies is a fundamental driver driving global market expansion. The global Integrin beta 8 market is growing due to an increase in the number of people suffering from various health problem.

Source: Prophecy Market Insights

The global Integrin beta 8 market is segmented based on disease, application, and region.

On the basis of Disease, the global Integrin beta 8 market is segmented into Arteriovenous malformation and Arrhythmogenic right ventricular cardiomyopathy. Based on Application, the target market is segmented into Flow cytometry, CyTOF and Others.

Regional Insights:

On region the global Integrin beta 8 market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Integrin beta 8 market report based on disease, application, and region.

Global Integrin Beta 8 Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Integrin beta 8 market includes Bio-Rad, LifeSpan Biosciences, OriGene, RanD system, Corbus Pharmaceuticals and Others.

• Bio-Rad.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• LifeSpan Biosciences
• RanD System
• OriGene
• Corbus Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section